Sunir Joshi

Ophthalmology

1465 Satellite Boulevard Northwest
Suwanee, GA 30024

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Journal: Therapeutic advances in ophthalmology

Published: April 02, 2026

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial.

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial.

Journal: Ophthalmology

Published: March 05, 2025

Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Journal: Therapeutic advances in ophthalmology

Published: November 27, 2024

Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.

Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.

Journal: JAMA ophthalmology

Published: November 16, 2023

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.

Journal: Lancet (London, England)

Published: September 26, 2023

Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration.

Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration.

Journal: Cureus

Published: June 07, 2023

Reply to Comment on: A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.

Reply to Comment on: A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.

Journal: American journal of ophthalmology

Published: June 03, 2020

A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.

A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.

Journal: American journal of ophthalmology

Published: December 19, 2019

Showing 1-8 of 8

Last Updated: 09/26/2026